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Abstract
Background: The number of bariatric procedures has exponentially increased in the past decade, as a result of the
lack of successful clinical weight-loss interventions. The main reasons for the failure of clinical obesity management
are: (1) anti-obesity medications are administered as monotherapies (or pre-combined drugs); (2) lack of combination
between pharmacotherapy and non-pharmacological modalities; (3) short duration of pharmacotherapy for obesity; (4)
lack of weight-loss maintenance strategies; (5) misunderstanding of the complex pathophysiology of obesity; and (6)
underprescription of anti-obesity medications. We developed a protocol that can potentially overcome the drawbacks
that may lead to the failure of clinical therapy for obesity. The aim of this study is therefore to report the clinical and
metabolic effects of our proposed obesity-management protocol over a 2-year period, and to determine whether this
more intensive approach to obesity management is feasible and a possible alternative to bariatric surgery in patients
with moderate-to-severe obesity.
Methods: This retrospective study involved 43 patients in whom bariatric surgery was indicated. Patients underwent
an intensive anti-obesity protocol that included pharmacotherapy with multiple drugs; intense surveillance with
monthly body analysis by air-displacement plethysmography, electrical bioimpedance, and 3D body scans; weekly
psychotherapy; diet planning with a dietician every 2 months; and exercises at least 3 times a week with exercises
prescribed by a personal trainer at least once a month. Body weight (BW), total weight excess (TWE), obesity class,
body mass index, fat weight, muscle weight, waist circumference, and visceral fat were analyzed. Markers of lipid and
glucose metabolism, liver function, and inflammation were also evaluated. Therapeutic success was defined as >20%
BW loss or >50% decrease in TWE after 1 year.
Results: Significant improvements were observed in all clinical and metabolic parameters. Thirty-eight (88.4%) patients
achieved 10% BW loss, and 32 (74.4%) achieved 20% BW loss. TWE decreased by >50% in 35 (81.4%) patients. Forty
(93.0%) patients were able to avoid bariatric surgery.
Conclusion: An intensive clinical approach to obesity management can be an effective alternative to bariatric surgery,
although further randomized controlled studies are necessary to validate our findings.
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Background
In recent years, the number of bariatric procedures has
increased, and almost 200,000 bariatric surgeries were
performed in the USA in 2015 [1]. The prevalence of
obesity has exponentially increased in the past decade,
particularly, that of the severest classes of obesity for
which current clinical approaches are not effective.
Surgical intervention for moderate and severe obesity,
when correctly recommended, leads to significant im-
provement in metabolic parameters [2, 3], remission of
diabetes [2], improvement in beta-cell function [2] and
normalization of glucose levels [3] as well as improve-
ments in inflammatory markers [4], reduction of long-
term cardiovascular risk [4, 5], cancer risk [6, 7], long-
term mortality [5, 8], and moreover, it is a safe proced-
ure [9]. These outcomes justify the formal recommenda-
tion of bariatric surgery for patients with a body mass
index (BMI) of >40 kg/m2 (or >35 kg/m2 in the presence
of comorbidities), according to the latest guidelines jointly
issued by The Obesity Society (TOS), the American Heart
Association (AHA), and the American College of
Cardiology (ACC) [10].
The same guidelines also recommend that surgical
intervention should be recommended only after the pa-
tient has: (a) attempted, unsuccessfully, to lose weight
via clinical obesity-management strategies for at least
2 years, (b) been made aware of the lifelong limitations
he/she will face after undergoing bariatric surgery, and
(c) achieved a weight loss amounting to at least 5% of
the total body weight (BW). However, the above require-
ments are not always followed by health-care providers
[11, 12], and many individuals who undergo bariatric
surgery have not previously attempted to lose weight
clinically, have not been assessed by a multidisciplinary
team [12, 13], and are not aware of the patient’s role, re-
sponsibilities, and limitations after the surgery [13, 14].
The large increase in bariatric procedures and the
waiving of attempts at clinical therapy in patients with
obesity classes II and III (BMI > 35 kg/m2) [15] are pos-
sibly attributable to the fact that in the past, clinical
weight-loss interventions have not been successful
enough to avoid bariatric procedures [16, 17]. Indeed,
most bariatric surgeries are probably attributable to a
lack of suitable clinical alternatives for obesity manage-
ment [18]. Recent reviews [16–18] have proposed the
following possible reasons for the failure of clinical obes-
ity management: (1) Anti-obesity medications are typic-
ally administered as monotherapies, even though it is
known that none of the available drugs can achieve more
than 10% of the weight-loss goal [14, 17]. In contrast, a
combination of different medications for obesity may
exhibit synergistic effects and provide results that are
better than the sum of the weight loss attributable to
each drug [17, 18]. Such a synergistic effect has been
demonstrated with different drug combinations [19–23],
and combination treatment is recommended by the
most recent obesity guidelines issued by the American
Association of Clinical Endocrinologists (AACE) [24],
despite an unwillingness on the part of medical doctors
and health insurance companies to apply combined
pharmacotherapy, even though this is largely accepted
for other disorders (2). In both research and clinical
practice [25], pharmacotherapy is not effectively com-
bined with other interventions, such as psychotherapy,
surveillance, and intensive diet, even though it is known
that the combination of different modalities can achieve
tangible and optimized outcomes [25–27]. (3) Pharma-
cotherapy for obesity is not prescribed over the long
term, despite evidence of the safety and benefits of the
long-term, on-label use of current anti-obesity medica-
tions [27, 28]. (4) There is a lack of weight-loss mainten-
ance strategies, although some studies have proposed
successful approaches to prevent weight regain [27, 29].
(5) The complex pathophysiology [27, 30] of obesity and
its multiple etiologies that are present in every patient
are frequently misunderstood. Such an understanding is
critical to provide psychological support [12, 31] allied
to intensive lifestyle modification [26], and its lack has
arguably led to a decline in diet, physical activity and
weight counseling [15]. (6) Anti-obesity medications are
greatly underprescribed, as only 2% of patients with
obesity (BMI > 30 kg/m2) have been prescribed anti-
obesity drugs [32].
Regarding the feasibility of clinical interventions to
classes II and III of obesity, anti-obesity drugs are
able to provide up to 10% of the total weight-loss
goal [24, 27], such as the combination of topiramate
and phentermine [20], liraglutide [33], combination of
bupropion and naltrexone [34], and lorcaserin [35].
Thus, drug treatment cannot induce adequate weight loss
in subjects with moderate and severe obesity, if provided
as monotherapy and not associated with other treatment
modalities [16, 17, 24], but there is enough evidence to
show that a multi-disciplinary, intensive and long-term
approach and surveillance can lead to results comparable
to those of surgical treatments [17, 24–29].
“Lifestyle modifications”, which still rely on general
diet counseling and physical activity recommenda-
tions, seem to be unhelpful if not intensified and in-
dividualized [26]; moreover, they do not provide the
minimum weight loss required to achieve risk reduc-
tion in most patients [24–27], and do not satisfy pa-
tients in the same way as pharmacotherapy and
surgery do [36]. Nevertheless, weight-loss strategies
have remained mostly unchanged [24, 26, 27], des-
pite evidence of their inefficacy. However, a few new
diet strategies, such as intermittent fasting diet and
alternate day fasting [37–41], which significantly
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change the relationship of obese patients with the
food-reward system, have shown promising results
[37–40].
Considering the aforementioned facts, as well as the
unfeasibility to perform bariatric surgery in all recom-
mended patients, due to the high prevalence of morbid
obesity (10% women, 8% men and one in every six
African American women has a BMI > 40 kg/m2 in the
USA) [41], we developed a protocol that can potentially
overcome the drawbacks that may lead to the failure of
clinical therapy for obesity.
Our protocol aimed to improve clinical anti-obesity
therapy outcomes, and was therefore based on the
following: (1) the identification and improvement of
previous approaches, (2) the combination of different
strategies that may have synergistic effects, and (3) ag-
gressive clinical intervention. We did not hesitate to
combine different modalities and optimize current ther-
apies, as we consider that this approach may be the most
effective way to clinically overcome obesity, especially
among subjects in whom previous attempts at clinical
obesity management have failed.
This protocol may be useful for patients who are
considering bariatric surgery but have not yet tried
clinical therapy, and may serve as an effective alterna-
tive in patients who are unable to undergo bariatric
surgery.
The aim of this study is therefore to report the clinical
and metabolic effects of our proposed obesity-
management protocol over a 2-year period, and to deter-
mine whether this more intensive approach to obesity
management is feasible and a possible alternative to bar-




The proposed interventions include a combination of
different strategies, as shown below:
1. Pharmacotherapy
a. Phase 1. Aggressive pharmacotherapy, with a
combination of both on- and off-label drugs,
according to a guideline that we proposed and is
detailed in Fig. 1, allied to regular follow-up with
a medical doctor every 2 months.
There were two possible scenarios for
pharmacotherapy: presence or absence of
contraindications to centrally acting drugs. For
each possibility, a preferred order of drugs was
determined, based on the safety and effectiveness
profiles of each drug. The combination of all the
proposed drugs, whenever feasible, was the first
choice of therapy.
Liraglutide 1.8 mg once a day, orlistat 120 mg
B.I.D. before meals, and the sodium glucose
transporter-2 (SGLT-2) inhibitor canagliflozin
300 mg once a day were prescribed for all
patients, except for those who had contraindications
to these drugs or who had not tolerated any of these
drugs in previous attempts. Metformin was
prescribed at a dose of 2000 mg a day when insulin
resistance was found by homeostatic model
assessment-insulin resistance (HOMA-IR) > 2.7.
Testosterone was prescribed for men with initial
testosterone levels <350 ng/dL and no contraindica-
tions to testosterone use (i.e., no history of prostate
cancer, prostate-specific antigen < 4.0 ng/mL and
hematocrit < 50%); 1000 mg testosterone
Fig. 1 Guideline of pharmacotherapy intereventions against obesity
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undecanoate (Nebido – Bayer, Germany) was
intramuscularly injected every 90 days in eligible
subjects. For women with initial testosterone levels
below 14 ng/dL (measured on three different
occasions to account for inaccuracies in the test) and
no history of thrombosis, a dose of 2.0 mg a day was
prescribed as a compounded topical cream.
We screened all patients for psychiatric disorders
prior to the prescription of centrally acting
medications, as recommended by the AACE
guidelines [24]. Subjects who did not present any
suspicion of psychiatric disorders and had no
contraindications to these classes of drugs were
offered the following:
Sibutramine 15 mg once a day was prescribed for
every patient who did not have uncontrolled
diabetes, hypertension or high cardiovascular risk,
as required by the Brazilian National Health
Surveillance Agency (ANVISA), and who had not
developed depression with sibutramine use in
previous attempts at weight loss.
Topiramate 50 mg B.I.D. was optionally added to
sibutramine, whenever carbohydrate binging was
detected. In our clinical practice, we noticed that
sibutramine plays a similar role as phentermine
when added to topiramate.
Lisdexamfetamine 50 mg was prescribed when
binge eating disorder (BED) was identified,
although by the end of the study, we still did not
have access to this medication. We screened all
subjects for BED, as recommended by the AACE
guidelines [24].
Bupropion 150 mg B.I.D. along with naltrexone
16 mg B.I.D. was prescribed when both
carbohydrate binging and excessive alcohol intake
were noticed.
Sertraline 100 mg once a day was offered when
anxiety was found to be an underlying cause of
obesity.
The centrally acting medications were also used
in combination, except for sibutramine and
sertraline (we do not recommend the
combination of sibutramine and lisdexamfetamine
as well). They were also allied to peripherally
acting medications.
b. Phase 2. Slow weaning off of anti-obesity
medications
Specific guidelines or articles about the
discontinuation of obesity drugs are almost
absent; therefore, all the features of the
proposed weaning-off process were based on
the rationale of obesity pathophysiology and on
the mechanism of action of each drug. The
weaning-off process is presented in Figs. 2, 3
and 4.
c. If a patient regained more than 10% of previously
lost weight, he or she was offered a “rescue
therapy” (Fig. 5), which consisted of the
reintroduction of all medications at the full doses,
but for a shorter period. Once weight loss was
achieved again, the weaning-off process was
restarted, this time at a slower rate.
2. Non-pharmacological approaches
Subjects were offered and were required to be
followed up for three non-medical modalities:
a. Behavioral therapy. A psychologist provided
cognitive behavioral therapy (CBT) that could be
done outside the clinic. The adherence criteria
Fig. 2 Finding the right moment to start the weaning-off process
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were regular follow-up for at least 1 year with
45 min of therapy sessions per week.
b. Exercises. A certified personal trainer, either from
the clinical staff or outside, provided monthly
follow-up and prescribed exercise regimens that
were to be followed at least three times a week.
The exercise training consisted of 40 min of
moderate-to-intense resistive and cardiovascular
exercises (>3 METs, World Health Organization)
[42]. Subjects were required to adhere to the
training program for at least 10 months in a year
(2 months of absence were allowed due to
vacations). Subjects had to fulfill the criteria for
exercise frequency, regularity and intensity in
order to be considered adherents. Additionally,
the personal trainers had to provide feedback
about the performance and adherence to
exercises for each subject, whenever the subjects
practiced outside the clinic.
c. Diet prescription. A 500–1500-kcal deficit was
aimed for via a hypocaloric diet consisting of
50–55% carbohydrates, 20–25% lipids and 20–
30% protein. Additionally, 0.2–0.4 g/kg/day of
whey protein was prescribed (whey protein was
not taken into account in the calculation of the
calorie balance). Subjects were required to attend
follow-up appointments with a registered dietician
once in every 2 months. A 500-kcal deficit diet was
offered in patients with BMI < 40 kg/m2, whereas a
1000-kcal deficit diet was prescribed for subjects
with a BMI of 40–45 kg/m2. A 1500-kcal deficit
was prescribed in those with BMI > 45 kg/m2.
Fig. 3 Weaning-off steps
Fig. 4 Management of the following steps of the discontinuation process according to the response to the initial weaning off intervention
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Personalization of diets was performed according
to two aspects. First, subjects were actively required
to provide individual food preferences as well as
most visited restaurants and places to eat. From
this, menus and nutritional facts were assessed in
order to provide the best options for each place,
whenever the chosen meal or place could be
included in the diet plan. Second, a general list of
foods and ingredients was provided, and subjects
had to point out their preferences. With this
information, a specific weekly menu was sent to
each subject by the dietician. To be considered as
adherents, subjects were required to stick to their
prescribed diets, in terms of meal sizes and quality,
at least 80% of the time and regularly make
follow-up visits to a registered dietician
(at least six visits yearly).
3. Surveillance
Intense surveillance was provided as follows:
a. Weekly BW and waist circumference (WC)
measurements (every Tuesday) that were sent
online to the clinic chart.
b. Monthly body composition analysis with a
validated electrical bioimpedance device
(InBody770, BioSpace, South Korea) [43–46],
air-displacement plethysmography (Bod Pod,
CosMed, USA) [47], and 3D body scanning
(MyBodee, Styku, USA).
c. Regular phone calls performed every 2 weeks by a
clinic staff member, with active inquires of diet,
exercise, behavioral therapy and pharmacotherapy
adherences.
Subject selection
This study is a retrospective analysis of an intensive clin-
ical protocol for the management of obesity headed in a
private practice clinic that was offered to patients with
obesity who searched for an obesity therapy. Included
subjects started the protocol from Aug-2013 to Aug-
2014 and finished from Aug-2014 to Aug-2015, although
they were allowed to voluntarily continue the proposed
protocol after the end of the study. The inclusion criteria
for this study were as follows: (1) BMI > 40 kg/m2 or
>35 kg/m2 in the presence of comorbidities, such diabetes
or hypertension, which would fulfill the TOS/AHA/ACC
criteria for bariatric surgery; (2) age between 18 and
70 years; (3) minimum of 1 year of regular follow-up of all
the proposed interventions; (4) adherence to at least two
of the three non-pharmacological approaches, (5) absence
of medications that alter BW, body composition or meta-
bolic parameters (e.g., statins, fibrates, niacin, vitamin E,
pioglitazone, sulfonylureas and insulin).
Clinical outcome measures
The following clinical parameters were evaluated: BW,
total weight excess (TWE), BMI, fat weight (FW),
muscle weight (MW), WC, visceral fat (VF), and weight
regain (WR). BW, VF, MW, and WR were evaluated by
InBody 770 [42–45]. FW was analyzed by Bod Pod [46],
TWE was estimated by the calculation provided by
InBody 770 [44, 46], which considers mineral, water, and
muscle masses to determine the ideal weight. This calcu-
lation has been validated and can precisely define the
amount of excess fat [44–46]. Although body analysis
was performed monthly, we used only the initial and
final results (at 1 year after the initial results) of body
analysis in this study. The body analysis exams were per-
formed monthly in order to improve the level of surveil-
lance. Whenever a lack of FW, VF or BW loss or a gain
in any of these measures was observed, nutritional,
psychological and pharmacological reassessment was
performed in order to identify mistakes in the interven-
tion and modify whatever was identified as improper for
the patient.
Fig. 5 Rescue therapy (in case of weight regain)
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Subjects were required to perform self-measurements
of WC and BW on Tuesdays. Those who did not present
WC and BW losses in the first 3 months of the interven-
tions or presented with WC or BW gains at any time,
were reassessed. The purpose of this surveillance was to
prevent withdrawals and to optimize all aspects of the
proposed approach that were not fully personalized to
the subjects.
Metabolic outcome measures
The following markers of lipid and glucose metabolism
were assessed: triglycerides (TGs), low-density lipopro-
tein (LDL) and high-density lipoprotein (HDL) choles-
terol, alanine transaminase (ALT), gamma-glutamyl
transferase (GGT), glycated hemoglobin (HbA1c), fast-
ing insulin (FI), fasting glucose (FG), uric acid, and C-
reactive protein (CRP). HOMA-IR was calculated at the
beginning and at the end of the intervention.
The biochemical markers were measured prior to the
beginning of the interventions and after 1 year, and were
compiled into our study.
The biochemical assays used to measure metabolic
markers were as follows: enzymatic assays for TGs and
HDL, colorimetric enzymatic assay for uric acid, the
modified International Federation of Clinical Chemistry
method for ALT and GGT, chemiluminescence for basal
insulin, high-performance liquid chromatography for
HbA1c, hexokinase assay for glucose, and turbidimetry
for CRP. The LDL level was calculated by the Friedewald
formula.
The intervention was considered to have been success-
ful, in terms of bariatric surgery avoidance, when 20% of
the BW was lost, or the TWE was decreased by at least
50% after 12 months of therapy.
Statistical analysis
The mean, statististical significance and confidence
interval of each variable (clinical and metabolic parame-
ters) were thoroughly analyzed with standardized
methods and analysis of variance, by using Microsoft
Excel. All data was independently compiled and calcu-
lated twice, in distinct documents, and then compared,
in order to ensure that there would be no mistakes and
therefore provide more certainty and reliability.
Ethical approval
We do not have an ethics review committee at our insti-
tution. We followed the principles outlined in the
Declaration of Helsinki. The proposed protocol did not
provide new and experimental therapies but combined
already standardized modalities, and therefore, did not
require approval from an ethics committee.
Results
Baseline characteristics
A total of 43 subjects were included in this study (32
women and 11 men). The mean follow-up duration was
17.3 months (+-2.1 months), and the mean BMI at the
baseline was 43.08 kg/m2 (+-2.66 kg/m2). Of the 43
subjects, 13 were taking medications that interfered with
the measured metabolic parameters. Thus, the metabolic
analysis included only 30 subjects. Twenty (60.5%)
subjects had been recommended to undergo bariatric
surgery before this clinical intervention. Two subjects
withdrew from the therapy, but both were successfully
contacted and their results evaluated.
The following medications were prescribed to the
study subjects and used regularly throughout the inter-
vention (1 year): liraglutide, 39 (90.7%) subjects; SGLT2
inhibitors, 37 (86.0%) subjects; orlistat, 34 (79.1%)
subjects; metformin, 28 (65.1%) subjects; bupropion
combined with naltrexone, 25 (58.1%) subjects; sibutra-
mine, 23 (53.5%) subjects; topiramate, 13 (30.2%) sub-
jects; testosterone, 12 (27.9%) subjects; fluoxetine, 11
(25.6%) subjects; and sertraline, 10 (23.3%) subjects. Re-
garding partial use, one patient used liraglutide for less
than 6 months, and one used it for 6–11 months. Five
patients used SGLT inhibitors for less than 6 months,
and two used metformin for less than 6 months. Four
used orlistat for less than 6 months, and three used it for 6–
11 months. Two patients used bupropion with naltrexone
for less than 6 months, and ten used it for 6–11 months.
Sibutramine was used by three patients for less than
6 months, and topiramate was used by four subjects for less
than 6 months. One patient used sertraline for less than
6 months. Of the total number of partially used drugs (36,
with more than one instance of partial use in some patients),
32 (88.9%) were discontinued due to intolerance to the
drugs, while 4 (11.1%) were interrupted with no apparent
reason. A summary of this data is exposed in Table 1.
A total of 41 (95.3%) subjects adhered to the diet plans
according to the proposed criteria, whereas 33 (76.7%)
subjects underwent physical therapy according to the pro-
posed conditions, and 16 (37.2%) underwent regular psy-
chotherapy as stated in the protocol. Four subjects (9.30%)
underwent all the non-pharmacological approaches regu-
larly, and 39 (90.70%) followed two of the three non-
medical modalities. Although not specified in the study,
subgroup analysis of adherence to the various therapies,
i.e., physical therapy and psychotherapy, physical therapy
and diet plan, psychotherapy and diet plan, and to all three
approaches did not show any statistical differences in both
clinical and metabolic outcomes between these groups.
Clinical outcomes
BW, BMI, FW, TWE, WC, and VF were all significantly
reduced after 1 year of the intervention as compared
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with the baseline (Table 2). MW was decreased by 2.9 kg
on average, and accounted for only 9.2% of the total
weight loss. Thus, 82.1% of BW loss was from the loss of
fat mass. All 43 subjects (100.0%) achieved a minimum
of 5% BW loss. Thirty-eight (88.4%) subjects lost >10%
of their BW, while 32 (74.4%) lost >20% of their BW
(among which, only 5 subjects lost <50% of their TWE).
In total, 35 (81.4%) subjects lost more than 50% of their
TWE. However, eight of these did not lose more than
20% of their BW. Twenty (46.5%) subjects achieved their
desired WC (<94 cm).
All 43 patients were initially candidates for bariatric
surgery. Of these, three (7.0%) subjects did not achieve
sufficient BW loss to avoid this procedure, and were
therefore referred to a bariatric surgeon. The remaining
40 (93.0%) subjects continued to undergo clinical follow-
up after achieving 20% BW loss or a 50% decrease in
TWE, or both. In 31 (72.1%) subjects, the BMI was de-
creased by at least two classes of the BMI obesity classi-
fication. The overall goals achieved, in terms of both
clinical and metabolic outcomes, have been shown in
Fig. 6.
Metabolic outcomes
The TG, LDL cholesterol, ALT, GGT, BI, FG, HOMA-
IR, HbA1c, uric acid, and CRP values all significantly de-
creased after 1 year of the intervention as compared
with the baseline (Table 3). The HDL level did not
change significantly. Among the 30 evaluated subjects,
22 had abnormal ALT levels at the baseline (normal
range, 7.0–43.0 U/L). After the intervention, only four of
these subjects continued to have abnormal ALT levels,
yielding a remission rate of 81.8% (p < 0.001). The
HOMA-IR value was elevated in 27 patients and nor-
malized in 22 patients, yielding a recovery rate of 81.5%
(p < 0.001) for insulin sensitivity.
Discussion
Pharmacotherapy
Historically, anti-obesity pharmacotherapy has been
improperly managed due to (a) the too short-term
drug prescriptions [16, 28, 29, 48], (b) lack of weight
maintenance follow-up [16, 27, 29, 49, 50], (c) lack of
pharmacological combinations [16–18, 30], and (d)
undertreatment [16, 51], since only 2% of patients
Table 1 Pharmacotherapy






LIRAGLUTIDE 1.8 mg daily Off-label (during the study period)
On-label (2016 Nov)
39 (90.7%) 1 < 6 months
1 6–11 months
SGLT2 INHIBITORS Canagliflozin 300 mg daily
Dapagliflozin 10 mg daily
Off-label 37 (86.0%) 5 < 6 months
ORLISTAT 120 mg B.I.D. On-label 34 (79.1%) 4 < 6 months
3 6–11 months
METFORMIN 2000 mg daily Off-label 28 (65.1%) 2 < 6 months
BUPROPION +
NALTREXONE
300 mg + 32 mg daily On-label (USA)
Off-label (Brazil)
25 (58.1%) 2 < 6 months
10 6–11 months
SIBUTRAMINE 10-15 mg daily On-label (Brazil)
Prohibited (USA)
23 (53.5%) 3 < 6 months
TOPIRAMATE 100 mg daily On-label (USA)
(when combined with phentermine)
Off-label (Brazil)
13 (30.2%) 4 < 6 months
TESTOSTERONE 1000 mg I.M. every 3 months On-label
(when hypogonadism is present)
12 (27.9%) -
FLUOXETINE 20-60 mg daily Off-label 11 (25.6%) 1 < 6 months
SERTRALINE 50-200 mg daily Off-label 10 (23.3%) 1 < 6 months
Table 2 Clinical responses to intervention
Baseline After intervention Change
Body weight (kg) 121.6 90.3 −31.3 (−25.7%; p < 0.001)
BMI (kg/m2) 43.08 31.99 −11.09 (−25.7%; p < 0.001)
Fat weight (kg) 55.4 29.7 −25.7 (−46.4%; p < 0.001)
Total weight excess (kg) 45.2 18.1 −27.1 (−60.0%; p < 0.001)
Waist circumference (cm) 131.2 99.4 −23.1 (−17.6%; p < 0.001)
Visceral fat (cm2) 263.8 101.0 −162.8 (−57.9%; p < 0.001)
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with obesity are prescribed pharmacological treatments
[51]. Obesity involves multiple central and peripheral
mechanisms to prevent weight loss and induce weight re-
gain after a period of weight loss, such as decreased rest-
ing metabolic rate and enhanced food-reward circuit
sensitivity [16, 27, 29, 49]. Thus, a combination of multiple
drugs, whenever there are no harmful interactions, is
more adequate and effective than monotherapy, as dem-
onstrated in several studies [16–25]. Likewise, long-term
therapy tends to be more successful, particularly, for
weight-regain prevention [48], given the fact that meta-
bolic adaptations after weight loss tend to persist for sev-
eral years afterwards [27, 29, 52], which makes weight loss
maintenance challenging [16, 27–29, 49, 50]. Indeed, the
AACE obesity guidelines recommend the avoidance of
short-term therapy (less than 6 months) due to the proven
safety profile and superiority of the long-term use of all
the available anti-obesity drugs. The guidelines also rec-
ommend a combination of drugs [24], as “appetite regula-
tion involves multiple pathways, and targeting more than
one pathway concurrently may have additive or synergistic
effects” [24].
The proposed pharmacotherapy protocol in the
present study, therefore, relied on the long-term pre-
scription of a combination of many medications. The
prescribed non-centrally acting drugs (medications that
do not alter neurotransmitter production or signaling)
were as follows:
(1)Liraglutide, a GLP-1 analogue, which has been
approved for long-term obesity treatment [33, 48],
and has wide peripheral and central actions,
including a central action on newly discovered
GLP-1 pathways [53–55];
(2)Orlistat, a lipase inhibitor, has been extensively
proven to be safe and effective, and has exhibited
other benefits besides weight loss, such as effects on
non-alcoholic steatohepatitis (NASH) [55] and
glycemic control [56–58];
(3)SGLT2 inhibitors, which are anti-diabetic drugs
that promote weight loss due to glycosuria and
calorie loss through urine; they were used here as
off-label therapy for obesity. Additionally, the
SGLT2 inhibitor empagliflozin has been shown to
Fig. 6 Goals achieved by patients
Table 3 Metabolic findings after clinical intervention
Baseline After intervention Change
TG (mg/dL) 177.4 81.0 −96.4 (−54.3%; p < 001)
LDL (mg/dL) 118.1 98.8 −19.3 (−26.3%; p < 0.05)
ALT (U/L) 52.9 27.8 −25.1 (−47.4%; p < 0.001)
GGT (mg/dL) 47.8 15.2 −32.6 (−68.2%; p < 0.001)
Basal insulin (μIU/mL) 23.1 7.9 −15.2 (−65.8%; p < 0.001)
Fasting glucose (mg/dL) 91.4 77.5 −13.9 (−15.2%; p < 0.001)
HOMA-IR 5.21 1.51 −3.7 (−70.8%; p < 0.001)
Uric acid (mg/dL) 7.1 5.7 −1.4 (−19.7%; p < 0.001)
CRP (mg/L) 0.73 0.39 −0.34 (−46.6%; p < 0.001)
HbA1c (%) 5.87 5.15 −0.72 (−13.6%; p < 0.001)
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reduce cardiovascular risks [59], an effect that is
expected to be common to this entire class of
drugs [60]. SGLT2 inhibitors are also effective for
weight loss in non-diabetic patients [61], and have
probable synergistic effects with GLP-1 analogues
on both glycemic control and weight loss [61].
SGLT2 inhibitors induce gluconeogenesis and
increase glucagon and GLP-1 levels, which may
contribute to fat loss [62]. In fact, it is been
found that SGLT2 inhibitors can be effective as
monotherapy for non-diabetic subjects and can
enhance weight loss as an add-on therapy to
GLP-1 analogues [63];
(4)Metformin, a muscle and liver insulin sensitizer, can
promote weight loss, especially when insulin
resistance is found [64, 65]; and
(5)Testosterone was prescribed whenever its deficiency
was detected and there were no contraindications, as
it has been shown to promote fat loss when
hypogonadism and obesity are present together, and
improves several metabolic parameters, particularly,
in men [66, 67].
Among centrally acting drugs, the proposed medica-
tions used in this study were as follows:
Sibutramine, a noradrenaline and serotonin reuptake
inhibitor, has been prohibited in some countries, but its
use is still allowed, under strict control, in Brazil. The
prohibition of sibutramine in some countries was due to
the SCOUT study [68], which showed an 11% increase
in cardiovascular events with sibutramine use. However,
several issues were found in regards to the design of this
trial: (a) subjects who were at a high risk of cardiovascu-
lar disease were included, which is questionable since a
high cardiovascular disease risk is a relative contraindi-
cation to sibutramine use; (b) the medication was main-
tained in patients who did not exhibit weight loss,
despite the standardized recommendation of interrup-
tion of sibutramine in case of non-responsiveness; (c)
subgroup analysis, although not the primary objective,
showed that among subjects who were at a high risk of
cardiovascular disease, weight loss was associated with a
decrease in this risk, whereas among subjects who were
not at a high risk of cardiovascular disease, no correl-
ation was detected between weight loss and cardiovascu-
lar disease risk. Indeed, further studies involving post-
hoc analysis [69] and studies with large populations [70]
showed that the wide prohibition of sibutramine market-
ing might have been inappropriate for patients without
cardiovascular disease;
(1)Topiramate, originally developed as an anti-epileptic
agent, had its use extended to obesity management,
when combined with phentermine [20]. This is a safe
drug combination [71] that reduces carbohydrate
craving and calorie intake [72]. Topiramate also re-
duces insulin [20] and leptin [73] resistances, and
has been shown to exert direct lipolytic effects [74].
Topiramate as an add-on therapy to sibutramine
was a plausible alternative in our practice, as
phentermine is still not approved in Brazil.
(2)Bupropion with naltrexone, which is a combination
of a noradrenaline and dopamine reuptake inhibitor
and an opioid receptor antagonist with synergistic
effects, has been approved as an anti-obesity therapy.
It has been shown to induce even greater weight loss
than previously predicted (−9.2 kg versus −6.6 kg in
previous studies) [75]. Additionally, it reduces CRP
and WC, and increases HDLc [75].
Lorcaserin, a 5-HT2c receptor agonist, was not in-
cluded in our protocol, since this drug is not officially
approved in Brazil, despite its proven safety and efficacy
in different studies [35, 76, 77] and a possible effect on
BED [78–81]. We recently included lisdexamfetamine in
our protocol, even though the current study does not have
any subject in whom the drug was used. Lisdexamfeta-
mine has been shown to be effective against BED [82, 83],
which has been confirmed by a systematic review of ran-
domized controlled trials [84]. Several newly discovered
brain pathways that induce obesity [85–89] reinforce the
importance of centrally acting drugs in obesity, preferably
targeting more than one mechanism.
Diet
A personalized diet plan was employed for each subject,
according to their food preferences and social environ-
ment. Studies have shown that non-adherence to diets
occurs when individual aspects are not taken into ac-
count [26, 27, 31]. The addition of whey protein was
based on the findings of several studies that showed that
this source of protein can prevent fat gain with high-fat
diets, enhance fat loss with hypocaloric diets and consid-
erably improve metabolic parameters [90–93].
We did not require 100% diet adherence to classify the
subjects as adherents to the proposed diet plans. It has
been observed that intermittent diets, such as alternate
day fasting and intermittent fasting diet, allow periods of
free meals and have no negative impact on weight loss
[37–40] when the rest of the diet plan is strictly
followed. These diets also help to decrease long-term
BED [40]. When 100% diet adherence is not required,
social events and travels become feasible, as both situa-
tions induce diet escapes and further loss of adherence
to food recommendations.
BED is an expected disorder among patients with
obesity, particularly, in patients with BMI > 35 kg/m2,
more than 50% of whom are affected by compulsive
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eating disorders [27]. The active search for BED in these
patients is supported by AACE obesity guidelines [24].
Exercise
Although exercises may not be the best approach to pro-
mote weight loss in obesity, they do improve fat loss, help
avoid muscle loss and prevent weight regain by increasing
energy expenditure and decreasing BED symptoms [27].
Intensive surveillance of adherence to physical activity was
critical for the success of the proposed interventions.
Behavioral therapy
The role of behavioral therapy in obesity management is
well established [29–31], especially for weight maintenance,
when motivation decreases, as behavior plays a critical role
in the pathophysiology of obesity. Conversely, psychological
modalities of obesity management are being decreasingly
used [15], possibly due to the lack of professional education
on obesity [31]. Among the various types of psychother-
apies, the behavioral cognitive approach is the most studied
strategy for weight loss and has therefore been standardized
for obesity management [30, 31].
The lack of adherence to regular follow-up with psy-
chotherapists was possibly the result of a misbelief that
the behavioral approach is not necessary nor effective,
despite strong evidence of its efficacy [31]. We did not
require a psychotherapist who specialized in obesity,
since it is not feasible to conduct large-scale obesity
therapy with obesity specialists due to the high preva-
lence of this disorder. The only requirement was that
subjects be followed up with CBT approaches, based on
the evidence of this strategy of obesity management.
Surveillance
This study proposed three types of surveillance: the
assisted body analysis monthly surveillance, the regular
phone calls and the weekly self-surveillance. They were
employed independently in order to provide more in-
tense oversight. The importance of surveillance on the
efficacy of weight loss and maintenance strategies has
been broadly studied [94–98] and is a key aspect in the
success of both weight loss and maintenance.
Weekly self-surveillance was recommended to be per-
formed on Tuesdays, and not on Mondays, since week-
ends are the periods when patients are more likely to
increase carbohydrate and sodium intakes, with conse-
quent accumulation of glycogen (in the liver and mus-
cles) and retention of water, respectively. The excessive
carbohydrate and sodium intakes can add up to 3–4 kg
of extra weight, but this is quickly lost on the first day of
adequate diet, usually on Mondays [99]. Phone calls have
also been reported play a significant role in ensuring
long-term adherence to obesity therapy [100], which was
confirmed by us.
Assessments of responses to obesity-management therapies
The assessment of responses to obesity therapy should
go beyond mere BW measurements, and include evalua-
tions of metabolic parameters, WC, and FW, which are
accurate predictors of cardiovascular and metabolic risks
[27, 29]. BMI may not be an accurate parameter and can
mislead interventions [101–103]. One of the best ways
to evaluate the response to obesity-management therap-
ies is to analyze markers of glucose and lipid metabolism
and inflammatory markers, as these will more directly
predict risk reductions. Good clinical methods, such as
body composition analysis and WC measurements, also
improve the accuracy of response assessments. For ex-
ample, the prevention of lean mass loss is an important
goal of obesity management, and this parameter is
underestimated when BW is the only outcome analyzed.
Lean mass can be determined using body composition
analysis and estimated using WC. Approaches that pre-
serve muscle mass, such as resistive exercises, tend to be
underappreciated when weighing scales are the only tool
employed. Furthermore, the effectiveness of strategies
that induce intensive loss, such as bariatric procedures,
is overestimated by weighing scale measurements, owing
to intense muscle loss.
To ensure the quality of the methodology and the ac-
curacy of the results, it was important to exclude from
the metabolic analysis subjects who received medications
that improved metabolic markers. These improvements
were not related to the proposed intervention protocol,
and could falsely improve the final results. However, pa-
tients receiving on- and off-label drugs for obesity that
also improve metabolic markers were included in the
metabolic analysis, as they were prescribed these drugs
regardless of their baseline metabolic levels.
Metabolic and clinical outcomes
After the intervention, impressive improvements were
seen in markers of liver function, lipid metabolism, glu-
cose metabolism, and inflammation, and were better
than the improvements previously described in the lit-
erature [16–22, 33–35]. It is important to note that none
of the medications used in this study is indicated for the
correction of liver dysfunction. Therefore, the improve-
ments observed were secondary to FW loss and the
beneficial side effects of some of the drugs. The signifi-
cant clinical and metabolic improvements observed in
this study will probably reduce overall risks [27], an ef-
fect which is enhanced by the inherent protective car-
diovascular effects of some of the medications used in
this protocol, such as liraglutide [32], SGLT inhibitors
[59], metformin [65] and orlistat [19, 29].
Although anti-hyperglycemic medications were pre-
scribed, HbA1c dropped more than expected. The initial
HbA1c was less than 6.0%, and it is known that the
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lower the HbA1c level, the harder it is to decrease. The
reduction in inflammatory markers, such as CRP and
uric acid, was also attributable to general metabolic
changes, as no specific drugs were prescribed for these
markers. The improvements observed in this study were
greater than the sum of the previously described im-
provements attributable to each of the prescribed drugs
[20, 33–35]. Thus, synergistic effects of the different
drugs used in this study may explain these surprising
positive findings.
Normalization of liver transaminases was seen in most
patients, suggesting that clinical obesity management
may be attempted prior to specific etiological investiga-
tions and therapies for NASH. This approach may also
prevent unnecessary invasive procedures (such as liver
biopsy). Further studies investigating the quantitative
imaging and classification of NASH before and after
anti-obesity therapy, together with biochemical liver-
function analysis are recommended.
The highly selective loss of fat mass was possibly due
to the intensive body constitution surveillance and con-
sequent adjustments in terms of diet and exercise plans
(and also due to testosterone therapy in patients with
hypogonadism), which probably led to more significant
changes in metabolic parameters and WC.
Finally, this study showed that patients do not necessar-
ily need to follow up with all three non-pharmacological
interventions (CBT, physical therapy and diet plan) and
do not have to specifically follow certain therapies, since
there were no differences in results among the various
therapy groups, regardless of whether two or three inter-
ventions were regularly followed, or between different
combinations. Despite being the ideal approach, follow-up
with all three modalities can be tiring and time-
consuming, and patients are therefore less likely to adhere
all of these treatments in the long run.
Changes in anti-obesity strategies
Instead of introducing one intervention at a time and
evaluating the response to each intervention, we opti-
mized all the key aspects of the proposed protocol at
once, given that: (1) obesity is a complex, hard-to-
manage disease, (2) its prevalence and severity are
quickly increasing, and (3) many issues have been identi-
fied regarding the proposed current therapies. Further-
more, aggressive approaches induce greater weight loss,
which can positively predict long-term weight loss and
maintenance [104].
In our opinion, obesity is a too severe a disorder for
step-by-step approaches. It has several long-term conse-
quences, including a more than 500% increase in cardio-
vascular disease, 260% increase in overall mortality after
18 years of obesity [105], and increased public health
costs in more than 50% of subjects [106]. Owing to these
reasons, we considered an aggressive approach to obesity
management to be more suitable. Once the proposed
combination of interventions is demonstrated to be ef-
fective, then we suggest that the number, intensity and
agressiveness of the interventions be slowly decreased
until an optimal protocol that remains chronically effect-
ive is found.
Besides developing an aggressive therapeutic protocol
combining on and off-label medications, we were also
concerned with determining the optimal time period for
which medications should be taken as well as designing
a suitable discontinuation plan. We could not find any
information in the literature about when and how obes-
ity drugs should be weaned off. We therefore developed
a protocol based on the mechanisms of action and safety
profiles of the proposed drugs.
Although previous studies [10, 15, 24, 29] have recom-
mended a two-step approach (weight loss and weight
maintenance) to obesity management (Fig. 5), there is a
crucial period between these two steps that cannot be
part of either of these periods. Herein, we named this
in-between period as weight stabilization. This step
starts right after the achievement of the final body
weight, and the length of the weight-stabilization period
will depend on the amount of weight loss and duration
of previous obesity. The longer obesity was present, the
longer it takes to stabilize the new weight. It is import-
ant to point out that duration of this period is estimated
and therefore not precise, as there is no accurate pre-
dictor of how long a weight-stabilization period would
be necessary in each case. Our strategy has been illus-
trated in Figs. 6, 7, 8 and 9 to provide an easier under-
standing of the proposed therapy. The intervention was
continued after the end of the first year (the period of
this study) by 42 of the 43 subjects (one subject moved
out), once they understood the importance of long-term
therapy, and with whom we are currently applying the
proposed steps for weight loss, stabilization and super-
vised maintenance.
Rescue therapy was performed in two patients during
the study. One of them had lost 26.7 kg but regained
6.9 kg during the weaning-off process, after his mother’s
death; all the medications were re-prescribed in their full
doses. The other subject had an exacerbation of BED, and
consequently regained 9.3 kg of the 22.0 kg of previously
lost weight. We reintroduced all the medications and
added lisdexamfetamine at a daily dose of 50 mg. Both pa-
tients were able to fully lose the regained weight in a
period of less than 3 months, which reinforces the import-
ance of a prompt approach once weight regain is detected.
We consider it important to maintain as many aspects
of real life as possible during the proposed intervention,
for example by including programmed interruptions in
physical activity, allowing vacations and not having an
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obligation for 100% adherence to diet. We consider that
there is a theoretically higher chance of long-term suc-
cess when individuals with obesity do not stand apart
from their realities while undergoing obesity therapies.
All 43 subjects had tried to lose weight medically at least
twice, with medications, diet and exercises. However, the
amounts of the previous weight losses were less intense
and the duration of the weight losses were short, usually
less than 3 months (in 38 of 43 subjects).
The cost of the proposed therapy for a 2-year period is
five times less than the expected increase in costs due to
obesity complications [107–109]. Once effective weight
loss occurs, the protocol would be able to decrease costs
by more than US$600 billion over the next 20 years
[110]. Even though current approaches are still unable
to provide long-term reduction in health costs due to
weight regain, which is observed with most approaches
and enforces the rationale for the current lack of health
insurance coverage for obesity treatments [110].
Herein, we proposed a different way to express weight
loss: controlled obesity, not ex-obesity, similar to dia-
betic patients in whom glucose is normalized or to
hypertensive patients in whom blood pressure is con-
trolled. The practical difference in terms of naming the
weight-maintenance period as “controlled obesity” is that
it helps support the notion of long-term therapy, regard-
less of the types of intervention, as obesity is seen as a
current disease even in weight-controlled subjects.
Weight maintenance
Obesity approaches are often successful in inducing
weight loss, but not in preventing weight regain [29, 49],
due to several reasons: (1) no protocols or guidelines are















Fig. 8 First and second steps of obesity management proposed by the present protocol: 1. Weight loss; and 2. Weight stabilization
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standardized optimal period of drug use is lacking;
pharmacological strategies vary according to the clinical
judgment of the treating physician, and are not based on
any previous protocol or studies; (3) there is a loss of
motivation after the achievement of the final weight,
when the positive reward of losing fat fades away; and
(4) there is a lack of long-term studies with currently ap-
proved interventions.
The need of effective clinical approaches to obesity
management
The high prevalence of moderate and severe obesity
[41], particularly among lower income and scholarship
subjects [41] turns unfeasible to provide proper bariatric
surgery and follow-up to the whole population that has
formal indication for this procedure. Given this fact, an
effective clinical approach could be an alternative to help
millions of subjects with obesity.
Therefore, the objective of this study was to develop
an effective, holistic, clinical protocol for obesity man-
agement that can be implemented before bariatric sur-
gery. We developed this protocol by correcting the
historical mistakes in obesity interventions generally ob-
served in clinical studies, such as the dissociation be-
tween pharmacological and non-pharmacological
strategies, and the lack of combination drug therapies.
We speculated that these reasons could explain why
clinical therapy for obesity often fails.
Clinical management vs. bariatric surgery
To our knowledge, this is the first study to analyze an
intensive clinical approach to obesity management, in-
corporating combined pharmacotherapy and non-
pharmacological modalities as well as the systematic
evaluation of clinical and metabolic parameters. Indeed,
the commitment of the whole team to the protocol, the
quality of the diet plans, the monitoring of the adher-
ence to exercise regimens and psychotherapy combined
with continuous body surveillance allowed this clinical
protocol to serve as an alternative to bariatric surgery.
Although we did not perform a head-to-head compari-
son, the outcomes of this protocol are comparable to
those of bariatric surgeries, especially to sleeve gastrec-
tomy, and indicate that clinical strategies can be effective
in obesity management, especially when optimal and
synergistic strategies are selected. Our search for an ef-
fective strategy to avoid bariatric surgery was an attempt
to cease and possibly reverse the recent trend of the
trivialization of bariatric surgery. This trend is worri-
some because post-bariatric surgery patients must take
lifelong precautions that are not required from non-
surgical ex-obese subjects [13, 14, 30]. In our medical
practice, we found that many post-bariatric surgery pa-
tients were not always aware of the possible complica-
tions of the surgery and indeed, of the patients
responsibilities, which is corroborated by previous stud-
ies [13, 14].
Limitations of this study
We are aware that the proposed protocol is not easily
reproducible, not due to biological issues, but due to so-
cial and financial conditions of obesity therapy centers
and affected subjects. The drugs used are expensive and
are not usually covered by health insurance in the USA
and in Brazil. Furthermore, pharmaceutical industries
produce each of the proposed medications in separate
packages, which hampers the conducting of studies with
potential drug combinations. In fact, several issues in
fighting obesity with pharmacotherapy were highlighted
by a study [16], such as not treating obesity as a chronic
disease, lack of availability of other clinical strategies for
weight loss, culturally unacceptable adverse effects of












Fig. 9 Weight maintenance strategies to prevent weight regain
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anti-obesity agents, low sales performance of obesity
medications (which weakens the research for new mole-
cules), and lack of drugs covered by health insurance.
Besides the difficulty in reproducing this study, other
important limitations of our paper are the lack of a control
group, possibility of enhanced effects due to the placebo
effect, small number of subjects, and the retrospective na-
ture of the analysis, although none of the patients were
lost to follow-up. Despite these limitations, the impressive
results observed in the subjects are hardly questionable,
and support the hypothesis that anti-obesity interventions
should be aggressive, although this must be further evalu-
ated in controlled trials in future.
Final discussion
The results of this protocol highlight the feasibility of
clinical anti-obesity therapies in patients with moderate-
to-severe obesity as well as the need for a multidisciplin-
ary and aggressive clinical approach to the patient with
obesity prior to bariatric surgery, as this has been shown
to be more effective than isolated treatments. Anti-
obesity therapy, regardless of the type of practice, should
be offered as a combination of different strategies, and
pharmacotherapy must be a part of this therapy in order
to provide effecrtive management. Our anti-obesity ap-
proach is not easy to be implemented, as it requires sev-
eral professionals, and strict and continuous contact
with patients; however, as the results show, our approach
may be a good alternative for patients prior to bariatric
procedures. Secondary findings are also important to
note, such as remission of altered liver profile and im-
provements in several metabolic disorders, which con-
firm the efficacy of the proposed approach.
Conclusion
An intensive and aggressive clinical approach to obesity
management can be an effective alternative to bariatric
surgery, although further studies are required to confirm
our findings.
Abbreviations
AACE: American Association of Clinical Endocrinologists; ACC: American
College of Cardiology; AHA: American Heart Association; ALT: Alanine
transaminase; ANVISA: Brazilian National Health Surveillance Agency;
BED: Binge eating disorder; BMI: Body mass index; BW: Body weight;
CBT: Cognitive behavioral therapy; CRP: C-reactive protein; FG: Fasting
glucose; FI: Fasting insulin; FW: Fat weight; GGT: Gamma-glutamyl
transferase; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein;
HOMA-IR: Homeostatic model assessment-insulin resistance; LDL: Low-
density lipoprotein; MW: Muscle weight; NASH: Non-alcoholic steatohepatitis;
SGLT-2: Sodium glucose transporter-2; TG: Triglycerides; TOS: The obesity
society; TWE: Total weight excess; VF: Visceral fat; WC: Waist circumference;
WR: Weight regain
Acknowledgements
We acknowledge the support of the Corpometria Institute team, the
availability of the data, and the patients of Corpometria Institute, who
believed that a who helped with new approach to obesity could be an
effective and possible way to prevent them from bariatric surgery.
Funding
We declare that we were not funded materially or financially by any
organization, government or university.
Availability of data and materials
Corpometria Institute database and charts were responsible for providing all
the raw, compiled and generated data. The database is not public; however,
permission was not required once all the subjects of this study were
originally followed up by one of the authors, as stated by the Brazilian
medical association (Conselho Federal de Medicina).
Authors’ contributions
FAC conceived, carried out the experiments and analyzed data. GCD and GA
carried out the experiments and analyzed data. All authors were involved in writing
the paper and had final approval of the submitted and published versions.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
We declare that the consent for publication is not applicable to this study.
Ethics approval and consent to participate
The proposed study protocol did not introduce new or experimental therapies,
but analyzed standardized modalities allied, and therefore approval from an
ethics committee was not required. The exemption was issued by the national
review board and ethics committee system (Sistema CEP-CONEP – Plataforma
Brasil), which has formally authorized the intervention without submission to an
ethics committee, but required that we provided subjects written informed
consent to participate in the protocol, and containing all the benefits and
possible harmful effects of the use of the proposed drugs. We concern that
every patient was fully aware of the purpose of the protocol and signed
informed consent to participate, prior to beginning the proposed approach.
The principles outlined in the Declaration of Helsinki were followed.
Received: 2 September 2016 Accepted: 3 February 2017
References
1. Estimate of Bariatric Surgery Number 2011–2015 [Web page]. https://asmbs.
org/resources/estimate-of-bariatric-surgery-numbers. Accessed 6 Feb 2017.
2. Souteiro P, Belo S, Neves JS et al. Preoperative Beta Cell Function is
Predictive of Diabetes Remission After Bariatric Surgery. Obes Surg. 2017;
27(2):288–94.
3. Yska JP, van Roon EN, de Boer A, et al. Remission of type 2 diabetes mellitus
in patients after different types of bariatric surgery: a population-based
cohort study in the Unied Kingdom. JAMA Surg. 2015;150(12):1126–33.
4. Lee GK, Cha YM. Cardiovascular benefits of bariatric surgery. Trends
Cardiovasc Med. 2016;26(3):280–9.
5. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on
cardiovascular disease and mortality: a systematic review and meta-analysis.
Int J Cardiol. 2014;173(1):20–8.
6. Casagrande DS, Rosa DD, Umpierre D, et al. Incidence of cancer following
bariatric surgery: systematic review and meta-analysis. Obes Surg. 2014;24(9):
1499–509.
7. Upsala S, Sanguankeo A. Bariatric surgery and risk of postoperative
endometrial cancer: a systematic review and meta-analysis. Surg Obes Relat
Dis. 2015;11(4):949–55.
8. Telem DA, TAlamini M, Shroyer AL, et al. Long-term mortality rates (>8-year)
improve as compared to the general and obese population following
bariatric surgery. Surg Endosc. 2015;29(3):529–36.
9. Lazzati A, Audureau E, Hemery F, et al. Reduction in early mortality
outcomes after bariatric surgery in France between 2007 and 2012: A
nationwide study of 133,000 obese patients. Surgery. 2016;159(2):467–74.
10. Jansen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the
management of overweight and obesity in adults: a report of the American
college of cardiology/American heart association task force on guidelines and
the obesity society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.
11. Cadegiani FA. Recommendations for bariatric surgery – are some doctors
going too far? Obesity Week 2015; Los Angeles, EUA. 2015 Nov. Poster
Number: T-P-LB-3887.
Cadegiani et al. BMC Obesity  (2017) 4:9 Page 15 of 18
12. Schweiger U. Counseling intervention helps little in obesity. MMW Fortschr
Med. 2015;157(9):39.
13. Rouleau CR, Rash JA, Mothersill KJ. Ethical issues in the psychosocial assessment of
bariatric surgery candidates. J Health Psychol. 2016;21(7):1457–71.
14. De-Souza DA, Greene LJ. Nutritional issues in obese patients submitted to
bariatric surgery. Re. “bariatric surgery may not achieve intended outcomes
in all patients”. Nutrition. 2015;31(9):1184–5.
15. Kraschnewski JL, Scimanna CN, Stuckey HL, et al. A silent response to the
obesity epidemic: decline in US physician weight counseling. Med Care.
2013;51(2):186–92.
16. Gotthardt JD, Bello NT. Can we win the war on obesity with
pharmacotherapy? Expert Rev Clin Pharmacol. 2016;13:1–9.
17. Hussain HT, Parker JL, Sharma AM. Clinical trial success rates of anti-obesity
agents: the importance of combination therapies. Obes Rev. 2015;16(9):707–14.
18. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological
treatments for obesity with weight loss and adverse effects: a systematic
review and meta-analysis. JAMA. 2016;315(22):2424–34.
19. Vickers SP, Cheetham SC, Headland KR, et al. Combination of the sodium-
glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine
further improves the body-weight reduction and glucose homeostasis of
obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes. 2014;7:265–75.
20. Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination
phentermine and topiramate extended release in the management of
obesity. Expert Opin Pharmacother. 2015;16(8):1263–74.
21. Guisado-Macías JA, Méndez-Sánchez F, Baltasar-Tello I, Zamora-Rodríguez FJ,
Escudero-Sánchez AB, Vaz-Leal FJ. Fluoxetine, topiramate, and combination
of both to stabilize eating behavior before bariatric surgery. Actas Esp
Psiquiatr. 2016;44(3):93–6.
22. Frías JP, Guja C, Hardy E. Exenatide once weekly plus dapagliflozin once
daily versus exenatide or dapagliflozin alone in patients with type 2
diabetes inadequately controlled with metformin monotherapy (DURATION-
8): a 28 week, multicentre, double-blind, phase 3, randomised controlled
trial. Lancet Diabetes Endocrinol. 2016;4(12):1004–16.
23. Cadegiani FA et al. International Congress on Obesity 2016. Vancouver, BC,
Canada, May 2016. Oral Presentation : T4:S25:05.
24. Garvey WT, Mechanick JI, Brett EM. American association of clinical
endocrinologists and American college of endocrinology comprehensive
clinical practice guidelines for medical care of patients with obesity. Endocr
Pract. 2016;22 Suppl 3:1–203.
25. Wadden TA. Exploring synergies in the treatment of obesity. Postgrad Med.
2001;109(6 Suppl):29–33.
26. Tuah NA, Amiel C, Qureshi S, Car J, Kaur B, Majeed A. Transtheoretical
model for dietary and physical exercise modification in weight loss
management for overweight and obese adults. Cochrane Database Syst
Rev. 2011;1:CD008066.
27. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet.
2016;387(10031):1947–56.
28. Wharton S. Current perspectives on long-term obesity pharmacotherapy.
Can J Diabetes. 2016;40(2):184–91.
29. Montesi L, El Ghoch M, Brodosi L, et al. Long-term weight loss maintenance for
obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes. 2016;9:37–46.
30. Roerig JL, Steffen K. Psychopharmacology and bariatric surgery. Eur Eat
Disord Rev. 2015;23(6):463–9.
31. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity
in patients encountered in primary care settings: a systematic review. JAMA.
2014;312(17):1779–91.
32. Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular
outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
33. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.
0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
34. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus
bupropion on weight loss in overweight and obese adults (COR-I): a
multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2010;376(9741):595–605.
35. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of
lorcaserin for weight loss in obese and overweight adults: the BLOSSOM
trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.
36. Gupta S, Wang Z. Treatment satisfaction with different weight loss methods
among respondents with obesity. Clin Obes. 2016;6(2):161–70.
37. Tinsley GM, La Bounty PM. Effects of intermittent fasting on body composition
and clinical health markers in humans. Nutr Rev. 2015;73(10):661–74.
38. Kulovitz MG, Kravitz LR, Mermier C, et al. Potential role of meal frequency as
a strategy for weight loss and health in overweight or obese adults.
Nutrition. 2014;30(4):386–92.
39. Alencar MK, Beam JR, McCormick JJ, et al. Increased meal frequency
attenuates fat-free losses and some markers of health status portion-
controlled weight loss diet. Nutr Res. 2015;35(5):375–83.
40. Horne BD, Muhlestein JB, Anderson JL. Health effects of intermitente fasting:
hormesis or harm? A systematic review. Am J Clin Nutr. 2015;102(2):464–70.
41. Prelance of obesity in the USA. [Web Site] Stateofobesity.org. Data
published in Sep 2016. Last access: Oct 30th, 2016
42. Global Strategy on Diet, Physical Activity and Health. [Web Site]. http://www.who.
int/dietphysicalactivity/physical_activity_intensity/en/. Accessed 6 Feb 2017.
43. InBody770. Premium Solution for your health [Web Site]. http://inbody.com/
global/product/InBody770.aspx. Accessed 6 Feb 2017.
44. FDA approval for visceral fat estimation by InBody770 [Web Site]. https://
www.accessdata.fda.gov/cdrh_docs/pdf14/K141483.pdf. Accessed 6 Feb 2017.
45. Miller RM, Chambers TL, Burns SP, Godard MP. Validating InBody® 570 Multi-
frequency Bioelectrical Impedance Analyzer versus DXA for Body Fat
Percentage Analysis. Med Sci Sports Exerc. 2016;48(5 Suppl 1):991.
46. Johnson KD, Luedtke C, Romeo F. Body composition analysis comparison
between Air displacement plethysmography and direct segmental
bioelectrical impedance in a university student population. Med Sci Sports
Exerc. 2016;48(5 Suppl 1):992–3.
47. Hart PD, Jensen P. Reliability of body composition assessment using
generalizability theory (G-theory). Med Sci Sports Exerc. 2016;48(5 Suppl 1):992.
48. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a
systematic and clinical review. JAMA. 2014;311(1):74–86.
49. MacLean PS, Wing RR, Davidson T, et al. NIH working group report:
innovative research to improve maintenance of weight loss. Obesity
(Silver Spring). 2015;23(1):7–15.
50. Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight losses in the look
AHEAD study: factors associated with long-term success. Obesity
(Silver Spring). 2011;19(10):1987–98.
51. Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of
weight loss medications: a comparison of prescribing patterns of
antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;
24(9):1955–61.
52. Fothergil E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years
after “the biggest loser” competition. Obesity (Silver Spring). 2016;24:1612–9.
53. Hsu TM Hahn JD, Konanur VR, Lam A, Kanoski SE. Hippocampal GLP-1 receptors
influence food intake, meal size, and effort-based responding for food through
volume transmission. Neuropsychopharmacology. 2015;40:327–37.
54. Richard JE, Farkas I, Anesten F, et al. GLP-1 receptor stimulation of the
lateral parabrachial núcleos reduces food intake: neuroanatomical,
electrophysiological, and behavioral evidence. Endocrinology. 2014;155(11):
4356–67.
55. Ronveaux CC, et al. Glucagon-like peptide 1 interacts with ghrelin and
leptina to regulate glucose metabolismo and food intake through vagal
afferent neuron signaling. J Nutr. 2015;145(4):672–80.
56. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-
alcoholic fatty liver disease. Gut. 2017;66(1):180–90.
57. Lau DC, Teoh H. Current and emerging pharmacotherapies for weight management
in prediabetes and diabetes. Can J Diabetes. 2015;39 Suppl 5:S134–41.
58. Aldekhail NM, Logue J, McLoone P, Morrison DS. Effect of orlistat on
glycaemic control in overweight and obese patients with type 2 diabetes
mellitus: a systematic review and meta-analysis of randomized controlled
trials. Obes Rev. 2015;16(12):1071–80.
59. Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes,
and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
60. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and
comparison of sodium-glucose cotransporter 2 inhibitors in
pharmacokinetics, pharmacodynamics, and pharmacologic effects.
J Pharmacol Sci. 2016;130(3):159–69.
61. Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2)
inhibitors: current status and future perspective. Eur J Phar Sci. 2016;93:244–52.
62. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond
increased glucosuria: a review of the clinical evidence. Diabetes Metab.
2014;40(6 Suppl 1):S4–S11.
63. Cadegiani FA. SGLT-2 Inhibitors (SGLT2i) As Monotherapy Against Obesity:
Is It Feasible? International Conference on Obesity 2016. Vancouver, BC,
Canada. 2016 May. Poster T4:S25:18
Cadegiani et al. BMC Obesity  (2017) 4:9 Page 16 of 18
64. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight
loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes.
2013;121(1):27–31.
65. Bromage DI, Yellon DM. The pleiotropic effects of metformin: time for
prospective studies. Cardiovasc Diabetol. 2015;14:109.
66. Haider A, Yassin A, Haider KS, Doros G, Saad F, Rosano GM. Men with
testosterone deficiency and a history of cardiovascular diseases benefit from
long-term testosterone therapy: observational, real-life data from a registry
study. Vasc Health Risk Manag. 2016;12:251–61.
67. Yassin AA, Nettleship J, Almehmadi Y, Salman M, Saad F. Effects of
continuous long-term testosterone therapy (TTh) on anthropometric,
endocrine and metabolic parameters for up to 10 years in 115 hypogonadal
elderly men: real-life experience from an observational registry study.
Andrologia. 2016;48(7):793–9.
68. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on
cardiovascular outcomes in overweight and obese subjects. N Engl J Med.
2010;363(10):905–17.
69. Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I. The effect of
sibutramine prescribing in routine clinical practice on cardiovascular outcomes:
a cohort study in the United Kingdom. Int J Obes. 2015;39(9):1359–64.
70. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss
reduces cardiovascular outcomes: results from the sibutramine
cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):
523–30.
71. Jordan J, Astrup A, Engeli S, Narkiwwicz K, Day WW, Finer N. Cardiovascular
effects of phentermine and topiramate: a new drug combination for the
treatment of obesity. J Hypertens. 2014;32(6):1178–88.
72. Johnson JL, Rolan PE. Paradoxical topiramate-induced hyperphagia
successfully treated with phentermine in a woman with migraine. J Clin
Neurosci. 2015;22(8):1363–4.
73. Caricilli AM, Penteado E, de Abreu LL, et al. Topiramate treatment improves
hypothalamic insulin and leptin signaling and action and reduces obesity in
mice. Endocrinology. 2012;153(9):4401–11.
74. Martins CP, Souza CO, Marques S, et al. Topiramate effects lipolysis in 3T3-L1
adipocytes. Biomed Rep. 2015;3(6):827–30.
75. Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The
relationship between early weight loss and weight loss at 1 year with
naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016;
40(9):1369–75.
76. Apovian C, Palmer K, Fain R, Perdomo C, Rubino D. Effects of lorcaserin on
Fat and lean mass loss in obese and overweight patients without and with
type 2 diabetes mellitus: the BLOSSOM and BLOSSOM-DM studies. Diabetes
Obes Metab. 2016;18(9):945–8.
77. Greenway FL, Shanahan W, Fain R, Ma T, Rubino D. Safety and tolerability
review of lorcaserin in clinical trials. Clin Obes. 2016;6(5):285–95.
78. Xu P, Xu P, He Y, Cao X. Activation of Serotonin 2C Receptors in Dopamine
Neurons Inhibits Binge-like Eating in Mice. Biol Psychiatry. 2016;(16):32470–2.
79. Farr OM, Upadhyay J, Gavrieli A, et al. Lorcaserin administration decreases
activation of brain centers in response to food cues and these emotion-
and salience-related changes correlate with weight loss effects: a 4-week-
long randomized, placebo-controlled, double-blind clinical trial. Diabetes.
2016;65(10):2943–53.
80. Higgins GA, Silenieks LB, Altherr EB, MacMillan C, Fletcher PJ, Pratt WE.
Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of
food seeking behavior in male rats: Implications for understanding the
anti-obesity property of 5-HT2C receptor agonists. Psychopharmacology
(Berl). 2016;233(14):2841–56.
81. Serafine KM, Rice KC, France CP. Directly observable behavioral effects of
lorcaserin in rats. J Pharmacol Exp Ther. 2015;355(3):381–5.
82. McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T,
Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe
binge eating disorder: results of Two pivotal phase 3 randomized controlled
trials. Neuropsychopharmacology. 2016;41(5):1251–60.
83. Guerdjikova AI, Mori N, Blom TJ, et al. Lisdexamfetamine dimesylate in
binge eating disorder: a placebo controlled trial. Hum Psychopharmacol.
2016;31(5):382–91.
84. Fornaro M, Solmi M, Perna G, et al. Lisdexamfetamine in the treatment
of moderate-to-severe binge eating disorder in adults: systematic
review and exploratory meta-analysis of publicly available placebo-
controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016;12:
1827–36.
85. Campos CA, Bowen AJ, Schwartz MW, Palmiter RD. Parabrachial CGRP
neurons control meal termination. Cell Metab. 2016;23(5):811–20.
86. Kim ER, Wu Z, Sun H, et al. Hypothalamic Non-AgRP, Non-POMC, GABAergic
neurons Are required for postweaning feeding and NPY hyperphagia.
J Neurosci. 2015;35(29):10440–50.
87. Roman CW, Derkach VA, Palmiter RD. Genetically and functionally defined
NTS to PBN brain circuits mediating anorexia. Nat Commun. 2016;7:11905.
88. Alhadeff AL, Baird JP, Swick JC, Hayes MR, Grill HJ. Glucagon-like Peptide-1
receptor signaling in the lateral parabrachial nucleus contributes to the
controlo f food intake and motivation to feed. Neuropsychopharmacology.
2014;39(9):2233–43.
89. Guan X. The CNS, glucagon-like peptide-2 receptor in the control of energy
balance and glucose metabolism. Am J Physiol Regul Integr Comp Physiol.
2014;307(6):R585–96.
90. Pezeshki A, Fahim A, Chelikani PK. Dietary Whey and Casein differentially
affect energy balance, gut hormones, glucose metabolism, and taste
preference in diet-induced obese rats. J Nutr. 2015;145:2236–44.
91. Liisberg U, Myrmel LS, Fjære E, et al. The protein source determines the
potential of high protein diets to attenuate obesity development in C57BL/
6J mice. Adipocyte. 2016;5(2):196–211.
92. Belobrajdic DP, McIntosh GH, Owens JA. A high-whey-protein diet reduces
body weight gain and alters insulin sensitivity relative to red meat in wistar
rats. J Nutr. 2004;134(6):1454–8.
93. Shertzer HG, Woods SE, Krishan M, Genter MB, Pearson KG. Dietary whey
protein lowers the risk for metabolic disease in mice Fed a high-Fat diet.
J Nutr. 2011;141(4):582–7.
94. Madigan CD, Daley AJ, Lewis AL, Aveyard P, Jolly K. Is self-weighing an
effective tool for weight loss: a systematic literature review and meta-
analysis. Int J Behav Nutr Phys Act. 2015;12(1):104.
95. Madigan CD, Jolly K, Lewis AL, Aveyard P, Daley AJ. A randomised
controlled trial of the effectiveness of self-weighing as a weight loss
intervention. Int J Behav Nutr Phys Act. 2014;11:125.
96. Madigan CD, Aveyard P, Jolly K, Denley J, Lewis A, Daley AJ. Regular
self-weighing to promote weight maintenance after intentional weight
loss: a quasi-randomized controlled trial. 6. J Public Health (Oxf). 2014;
36(2):259–67.
97. Madigan CD, Jolly K, Roalfe A, Lewis AL, Webber L, Aveyard P, Daley AJ.
Study protocol: the effectiveness and cost effectiveness of a brief
behavioural intervention to promote regular self-weighing to prevent
weight regain after weight loss: randomised controlled trial (The LIMIT
Study). BMC Public Health. 2015;15:530.
98. Cadegiani FA. A continuous surveillance and follow-up can perpetuate
weight loss after discontinuing drugs for obesity. Obesity Annals 2015 Nov.
Presented at The Annual Meeting of the Obesity Society (TOS), Obesity
Week 2015, Los Angeles, 2015 Nov. Poster Number: T-P-LB-3825.
99. Tanenbaum ML, Ross KM, Wing RR. Overeat today, skip the scale tomorrow:
an examination of caloric intake predicting nonadherence to daily self-
weighing. Obesity (Silver Spring). 2016;24(11):2341–3.
100. Simpson SA, McNamara R, Shaw C, Kelson M, Moriarty Y, Randell E, et al. A
feasibility randomised controlled trial of a motivational interviewing-based
intervention for weight loss maintenance in adults. Health Technol Assess.
2015;19(50):371–8.
101. Joshy G, Korda RJ, Bauman A, Van Der Ploeg HP, Chey T, Banks E.
Investigation of methodological factors potentially underlying the
apparently paradoxical findings on body mass index and all-cause mortality.
PLoS One. 2014;9(2):e88641.
102. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality
with overweight and obesity using standard body mass index categories:
a systematic review and meta-analysis. JAMA. 2013;309(1):71–82.
103. Veronese N, Cereda E, Solmi M. Inverse relationship between body mass
index and mortality in older nursing home residents: a meta-analysis of
19,538 elderly subjects. Obes Rev. 2015;16(11):1001–15.
104. Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, et al. Weight
change in the first 2 months of a lifestyle intervention predicts weight
changes 8 years later. Obesity (Silver Spring). 2015;23(7):1353–6.
105. Guo F, Garvey WT. Cardiometabolic disease risk in metabolically healthy and
unhealthy obesity: Stability of metabolic health status in adults. Obesity.
2016;24(2):516–25.
106. Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime
cost of diabetes and its implications for diabetes prevention. Diabetes Care.
2014;37(9):2557–64.
Cadegiani et al. BMC Obesity  (2017) 4:9 Page 17 of 18
107. Ara R, Blake L, Gray L et al. What is the clinical effectiveness and cost-
effectiveness of using drugs in treating obese patients in primary care:
a systematic review. Health Technol Assess. 2012;16(5):1–195
108. Urban Institute, The New York Academy of Medicine and TFAH, 2008 [Web
page]. http://healthyamericans.org/reports/prevention08/Prevention08.pdf.
Accessed 6 Feb 2017.
109. Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR.
Beneficial effect of high energy intake at lunch rather than dinner on
weight loss in healthy obese women in a weight-loss program:
a randomized clinical trial. Am J Clin Nutr. 2016;104(4):982–9.
110. Zomer E, Leach R, Trimmer C et al. Effectiveness and cost-effectiveness of
interventions that cause weight loss and reduce the risk of cardiovascular
disease. Diabetes Obes Metab. 2017;19(1):118–124.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Cadegiani et al. BMC Obesity  (2017) 4:9 Page 18 of 18
